Novel clinical trial designs for treatment of ductal carcinoma in situ of the breast with trastuzumab (herceptin).
|
| Abstract |
Because ductal carcinoma in situ (DCIS) avidly expresses Her2/neu, the target of the monoclonal antibody trastuzumab, and because trastuzumab has been shown to be effective against invasive breast cancer, trastuzumab may be effective for reducing the tumor burden and abrogating or reversing the hypothesized transition from in situ to invasive disease in patients with DCIS. To test this hypothesis, a trial of neoadjuvant trastuzumab for DCIS has been opened at our institution. Because trastuzumab has been shown to act as a radiosensitizing agent for Her2/neu-overexpressing cancer and because there are currently no systemic treatments for estrogen-receptor-negative DCIS, it makes sense to investigate whether use of trastuzumab concurrently with postoperative radiation therapy improves local control of DCIS. The National Surgical Adjuvant Breast and Bowel Project (NSABP) is planning a trial to test this hypothesis. The risk of cardiac toxicity associated with the doses of trastuzumab planned for these trials (cumulative doses of 8 mg/kg for our trial and 14 mg/kg in the NSABP trial) is believed to be minimal, but the safety profile of these approaches will need to be closely monitored.
|
|---|---|
| Authors | Ricardo J Gonzalez, Aman U Buzdar, W Fraser Symmans, Tina W Yen, Kristine R Broglio, Anthony Lucci, Francisco J Esteva, Guosheng Yin, Henry M Kuerer |
| Journal | The breast journal (Breast J) 2007 Jan-Feb Vol. 13 Issue 1 Pg. 72-5 ISSN: 1075-122X [Print] United States |
| PMID | 17214797 (Publication Type: Journal Article) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!